Latest Alnylam News & Updates

See the latest news and media coverage for Alnylam. We track all announcements, press releases, and industry mentions in real time, all in one place.

Alnylam

Biopharmaceutical company developing RNA interference medicines

alnylam.com

Headquarters: Cambridge, United States
Founded year: 2002
Company type: Public company
Number of employees: 3,000–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Alnylam

In short: Alnylam achieved GAAP profitability and a $50 billion market cap following the FDA approval and successful launch of AMVUTTRA.

Company announcements

Today Alnylam

Alnylam partners with Borussia Dortmund women’s team

The collaboration aims to raise awareness about acute hepatic porphyria through community connections and disease education in Germany.

September 14 Alnylam

Alnylam shares RNAi Roundtable takeaways on zilebesiran for hypertension, [link]

Simon Fox highlights key insights from the program lead regarding this investigational therapy's potential in addressing cardiovascular risk and uncontrolled high blood pressure conditions.

17 December 2025 Alnylam

Alnylam invests $250 million to expand manufacturing capacity

The investment adds an enzymatic ligation platform to its Norton facility, approved by the FDA's Emerging Technology Program, to meet growing global demand for RNAi therapeutics.

20 March 2025 Alnylam

Alnylam gets FDA approval for AMVUTTRA to treat ATTR-CM

The RNAi therapeutic reduces cardiovascular mortality and hospitalizations, becoming the only approved treatment for both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Media coverage

August 30 Marketscreener

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

– Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients ...

August 16 The Globe and Mail

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Alnylam's stock has plunged due to a revenue guidance cut and other concerns. However, the full story for this biotech innovator is more positive than...

August 2 The Globe and Mail

Alnylam Q2 2026 Earnings Call Shows TTR Strength

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities...

30 October 2025 MSN

Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.

Highflying Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs...

Never miss news about Alnylam

Track Alnylam and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Alnylam competitors & trending companies

Browse news for competitors to Alnylam and other trending companies.